NINLARO

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, South Africa, Turkey, UK.

Active ingredients

The drug NINLARO contains one active pharmaceutical ingredient (API):

1	Ixazomib UNII 46CWK97Z3K - IXAZOMIB CITRATE
	Ixazomib is an oral, highly selective and reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of several tumour cell types in vitro. In vivo, ixazomib demonstrated antitumour activity in various tumour xenograft models, including models of multiple myeloma.
	Read more about Ixazomib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NINLARO Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XG03		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors
Discover more medicines within L01XG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	501118050029202, 501118050029302, 501118050029402
CA	Health Products and Food Branch	02456796, 02456818, 02456826
EE	Ravimiamet	1715037, 1734140, 1734162, 1849923
FI	Lääkealan turvallisuus- ja kehittämiskeskus	183869, 392242, 506187
FR	Base de données publique des médicaments	66833683, 69537091, 69663414
GB	Medicines & Healthcare Products Regulatory Agency	340205, 340211, 340215, 392458, 392460, 392462
HK	Department of Health Drug Office	65568, 65569, 65570
IE	Health Products Regulatory Authority	88957, 88958, 88959
IL	מִשְׂרַד הַבְּרִיאוּת	7816, 7817, 7818
JP	医薬品医療機器総合機構	4291049M1024, 4291049M2020, 4291049M3027
LT	Valstybinė vaistų kontrolės tarnyba	1081722, 1081723, 1081724
NL	Z-Index G-Standaard, PRK	139629, 139637, 139645
PL	Rejestru Produktów Leczniczych	100381826, 100381832, 100381849
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63372001, W63373001, W63374001
SG	Health Sciences Authority	15162P, 15163P, 15164P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699456150036, 8699456150043, 8699456150050
US	FDA, National Drug Code	63020-078, 63020-079, 63020-080, 63020-230, 63020-390, 63020-400
ZA	Health Products Regulatory Authority	51/26/0956, 51/26/0957, 51/26/0958